Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
Inventors
Khan, Muhammad-Tanweer • Backhed, Fredrik
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11260082-B2
Publication Date
2022-03-01
Expiration Date
Abstract
The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.
Core Innovation
The invention relates to probiotic treatment and prevention of diabetes and gastrointestinal and metabolic diseases by increasing butyrate production and/or increasing the levels of Faecalibacterium prausnitzii in the gut of a subject. The method administers a strain of Faecalibacterium prausnitzii together with a strain of Desulfovibrio piger, and the Desulfovibrio piger strain has one or more characteristics selected from producing acetate, consuming lactate, and being an electron acceptor.
The core concept is that the increase in butyrate production and/or the increase in the levels of Faecalibacterium prausnitzii is a synergistic effect of administering the Faecalibacterium prausnitzii strain and the Desulfovibrio piger strain. The disclosed rationale attributes the synergy to electron cross-talk or symbiosis between the organisms, promoting increased colonization of Faecalibacterium prausnitzii and increased butyrate production in the gut.
The document further supports the approach by describing preferred strains and associated identifiers for Faecalibacterium prausnitzii and Desulfovibrio piger, including Faecalibacterium prausnitzii DSM 32186 (FBT-22) and Desulfovibrio piger DSM 32187 (FBT-23). It also includes a genetic feature for Faecalibacterium prausnitzii, including an L-lactate dehydrogenase gene (EC 1.1.1.27). The background is directed to subjects having reduced butyrate production and/or reduced or low levels of Faecalibacterium prausnitzii, associated with dysbiosis and the listed disease conditions.
Claims Coverage
The claim set is centered on one independent claim, supported by dependent claims that refine the method by adding quantitative thresholds, administration timing, and specific strain and genetic features, while linking the subject condition to defined disease targets.
Synergistic administration to increase butyrate and/or Faecalibacterium prausnitzii levels
Administering to a subject having reduced butyrate production and/or reduced or low levels of Faecalibacterium prausnitzii in the gut a strain of Faecalibacterium prausnitzii and a strain of Desulfovibrio piger, wherein the Desulfovibrio piger strain has one or more characteristics of producing acetate, consuming lactate, and being an electron acceptor, thereby increasing butyrate production by Faecalibacterium prausnitzii and/or increasing the levels of Faecalibacterium prausnitzii in the gut, wherein the increase is a synergistic effect of administering the Faecalibacterium prausnitzii strain and the Desulfovibrio piger strain.
The coverage focuses on the synergistic combination of Faecalibacterium prausnitzii with Desulfovibrio piger characterized by acetate production, lactate consumption, and electron-acceptor activity, to increase butyrate production and/or Faecalibacterium prausnitzii levels in a subject with reduced butyrate and/or reduced or low Faecalibacterium prausnitzii.
Stated Advantages
Increasing butyrate production by Faecalibacterium prausnitzii and/or increasing the levels of Faecalibacterium prausnitzii in the gut of a subject.
Achieving the increase as a synergistic effect of administering the Faecalibacterium prausnitzii strain and the Desulfovibrio piger strain.
Documented Applications
Probiotic treatment and prevention of diabetes and gastrointestinal and metabolic diseases by increasing butyrate production and/or increasing Faecalibacterium prausnitzii levels in the gut.
Disease targets associated with reduced butyrate production and/or reduced or low levels of Faecalibacterium prausnitzii, including type 2 diabetes, gestational diabetes, obesity, inflammatory bowel disease, irritable bowel syndrome, gout, pouchitis, chronic kidney disease, psoriasis, frailty, and constipation.
Interested in licensing this patent?